<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82467">
  <stage>Registered</stage>
  <submitdate>10/12/2007</submitdate>
  <approvaldate>13/12/2007</approvaldate>
  <actrnumber>ACTRN12607000636459</actrnumber>
  <trial_identification>
    <studytitle>Gonadotropin-releasing hormone (GnRH) antagonist vs. gonadotropin-releasing hormone agonist protocol for in vitro fertilization in non-obese patients with Polycystic Ovary Syndrome (PCOS). A prospective randomized study.</studytitle>
    <scientifictitle>A prospective randomized study comparing clinical and embryological outcomes in controlled ovarian hyperstimulation protocols with GnRH antagonist and GnRH agonist for in vitro fertilization in PCOS non-obese patients.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>GnRH antagonists in PCOS</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Controlled ovarian hyperstimulation with GnRH antagonists (Cetrotide 0,25 mg/day; intramuscular; starting when the two follices reach the diameter of 14mm untill the criteria for human chorionic gonadotropin administartion) and agonists (Triptorelin 3,75 mg; intramuscular; once, on the 20-22 day of the preceding cycle),
intracytoplasmic sperm injection</interventions>
    <comparator>Active group, women stimulated with GnRH agonist in a standard long protocol</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Delivery per attempt, clinical pregnancy per attempt, implantation rate</outcome>
      <timepoint>Pregnancy was confirmed by pregnancy test 14 days after embryo transfer (ET) and by vaginal ultrasound scan at 6 and 12 weeks of gestation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Matured oocytes (M2) rate, fertilization rate, embryo quality,</outcome>
      <timepoint>Fertilizations checked 16-18 hours after intracytoplasmic sperm injection (ICSI)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. meeting of 2003 Rotterdam PCOS criteria; 2. age=40 years; 3. body mass index &lt;27 kg/m2; 4. FSH &lt; 12 mIU/ml on the 3rd day of the cycle; 5. negative screening for hepatitis B and C virus infection and human immunodeficiency virus (HIV) infection.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>&gt;2 miscarriages, &gt;3 unsuccessful IVF/ICSI cycles, anatomical abnormalities of the uterus on laparoscopy or hysteroscopy and existence of ovarian cysts.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Simple randomisation by using a randomisation table created by a computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>2/02/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Poland</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>State Committee for Scientific Research</primarysponsorname>
    <primarysponsoraddress>1/3 Wspolna Street
Warsaw 00-529 Poland</primarysponsoraddress>
    <primarysponsorcountry>Poland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>State Committee for Scientific Research</fundingname>
      <fundingaddress>1/3 Wspolna Street
Warsaw 00-529 Poland</fundingaddress>
      <fundingcountry>Poland</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>State Committee for Scientific Research</fundingname>
      <fundingaddress>1/3 Wspolna Street
Warsaw 00-529 Poland</fundingaddress>
      <fundingcountry>Poland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Pomeranian Medical University</sponsorname>
      <sponsoraddress>1 Rybacka Street
Szczecin 70-204 Poland</sponsoraddress>
      <sponsorcountry>Poland</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Many clinical trials demonstrate that overall outcomes are comparable in GnRH agonists and antagonists protocols. However, recent data suggest that the duration of stimulation as well as the incidence of severe OHSS are significantly reduced in COH protocols with GnRH antagonist. There are only few studies comparing clinical outcome of GnRH agonist and antagonist protocols in PCOS patients. Nevertheless, none of those studies include a detailed embryological description. Because obesity was reported to be associated with relative gonadotropin resistance as well as lower number of collected oocytes we excluded obese patients. Mentioned studies did not consider high BMI as an exclusion criteria.
In the current study, we decided to verify if women with PCOS can also benefit from GnRH antagonist protocol. Additionally, since the relative importance and the role of monitoring of LH in follicular development is still disputable we investigate correlation between LH levels and the treatment outcome.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ciepiela Przemyslaw</name>
      <address>Department of Reproductive Medicine and Gynecology
Pomeranian Medical University
2 Siedlecka Street
Szczecin-Police 72-010</address>
      <phone>+48 91 4256960</phone>
      <fax>+48 91 4256960</fax>
      <email>ciepiela@sci.pam.szczecin.pl</email>
      <country>Poland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ciepiela Przemyslaw</name>
      <address>Department of Reproductive Medicine and Gynecology
Pomeranian Medical University
2 Siedlecka Street
Szczecin-Police 72-010</address>
      <phone>+48 91 4256960</phone>
      <fax>+48 91 4256960</fax>
      <email>ciepiela@sci.pam.szczecin.pl</email>
      <country>Poland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ciepiela Przemyslaw</name>
      <address>Department of Reproductive Medicine and Gynecology
Pomeranian Medical University
2 Siedlecka Street
Szczecin-Police 72-010</address>
      <phone>+48 91 4256960</phone>
      <fax>+48 91 4256960</fax>
      <email>ciepiela@sci.pam.szczecin.pl</email>
      <country>Poland</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>